Asymmetry Capital Management L.P. boosted its stake in Puma Biotechnology (NASDAQ:PBYI) by 145.0% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 18,057 shares of the biopharmaceutical company’s stock after acquiring an additional 10,686 shares during the period. Puma Biotechnology comprises approximately 1.5% of Asymmetry Capital Management L.P.’s investment portfolio, making the stock its 23rd largest position. Asymmetry Capital Management L.P.’s holdings in Puma Biotechnology were worth $1,229,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of PBYI. Dimensional Fund Advisors LP purchased a new stake in Puma Biotechnology in the 3rd quarter valued at about $4,615,000. Schwab Charles Investment Management Inc. raised its holdings in Puma Biotechnology by 3.7% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 140,198 shares of the biopharmaceutical company’s stock valued at $13,859,000 after buying an additional 5,031 shares during the period. Strs Ohio raised its holdings in Puma Biotechnology by 425.9% in the 4th quarter. Strs Ohio now owns 14,200 shares of the biopharmaceutical company’s stock valued at $1,403,000 after buying an additional 11,500 shares during the period. Clear Harbor Asset Management LLC purchased a new stake in Puma Biotechnology in the 4th quarter valued at about $288,000. Finally, Rice Hall James & Associates LLC raised its holdings in Puma Biotechnology by 355.7% in the 4th quarter. Rice Hall James & Associates LLC now owns 106,272 shares of the biopharmaceutical company’s stock valued at $10,505,000 after buying an additional 82,953 shares during the period. Hedge funds and other institutional investors own 97.57% of the company’s stock.

Shares of NASDAQ:PBYI opened at $55.60 on Thursday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.87 and a current ratio of 1.91. The stock has a market cap of $1.96 billion, a price-to-earnings ratio of -7.08 and a beta of 0.18. Puma Biotechnology has a 1 year low of $54.00 and a 1 year high of $55.65.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.26) by $0.61. The business had revenue of $66.50 million for the quarter, compared to analysts’ expectations of $67.33 million. During the same quarter last year, the company earned ($1.16) earnings per share. analysts anticipate that Puma Biotechnology will post -3.94 EPS for the current fiscal year.

Several analysts recently issued reports on PBYI shares. Zacks Investment Research upgraded shares of Puma Biotechnology from a “sell” rating to a “hold” rating in a report on Friday, January 26th. BidaskClub upgraded shares of Puma Biotechnology from a “hold” rating to a “buy” rating in a research note on Saturday, February 17th. Credit Suisse Group set a $147.00 price target on shares of Puma Biotechnology and gave the stock a “buy” rating in a research note on Monday, January 22nd. Bank of America cut their price target on shares of Puma Biotechnology from $135.00 to $115.00 and set a “buy” rating on the stock in a research note on Wednesday, January 24th. Finally, Barclays cut their price target on shares of Puma Biotechnology from $92.00 to $90.00 and set an “overweight” rating on the stock in a research note on Friday, March 2nd. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Puma Biotechnology has a consensus rating of “Buy” and an average target price of $99.20.

Puma Biotechnology Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)).

Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology (NASDAQ:PBYI).

Institutional Ownership by Quarter for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.